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Abstract
Background In recent years, a significant number of
costly oral therapies have become available for the treat-
ment of pulmonary arterial hypertension (PAH). Funding
decisions for these therapies requires weighing up their
effectiveness and costs.
Objective The aim of this study was to assess the cost
effectiveness of monotherapy with oral PAH-specific ther-
apies versus supportive care as initial therapy for patients
with functional class (FC) II and III PAH in Canada.
Methods A cost-utility analysis, from the perspective of a
healthcare system and based on a Markov model, was
designed to estimate the costs and quality-adjusted life-
years (QALYs) associated with bosentan, ambrisentan,
riociguat, tadalafil, sildenafil and supportive care for PAH
in treatment-naı¨ve patients. Separate analyses were con-
ducted for cohorts of patients commencing therapy at FC II
and III PAH. Transition probabilities, based on the relative
risk of improving and worsening in FC with treatment
versus placebo, were derived from a recent network meta-
analysis. Utility values and costs were obtained from
published data and clinical expert opinion. Extensive sen-
sitivity analyses were conducted.
Results Analysis suggests that sildenafil is the most cost-
effective therapy for PAH in patients with FC II or III.
Sildenafil was both the least costly and most effective
therapy, thereby dominating all other treatments. Tadalafil
was also less costly and more effective than supportive care
in FC II and III; however, sildenafil was dominant over
tadalafil. Even given the uncertainty within the clinical
inputs, the probabilistic sensitivity analysis showed that
apart from sildenafil and tadalafil, the other PAH therapies
had negligible probability of being the most cost effective.
Conclusion The results show that initiation of therapy
with sildenafil is likely the most cost-effective strategy in
PAH patients with either FC II or III disease.
Key Points for Decision Makers
The results indicate that initiation of therapy with
sildenafil in patients with functional class (FC) II and
III PAH would result in probable cost savings
compared with riociguat, bosentan, ambrisentan
5 mg, ambrisentan 10 mg and tadalafil.
The study findings do not support differential
funding of PAH therapies for patients with FC II
versus FC III disease based on current evidence.
1 Introduction
Pulmonary arterial hypertension (PAH) is an uncommon
progressive condition characterised by increased pul-
monary vascular resistance which often leads to right
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ventricular heart failure and death [1]. Historically, most
cases of the disease were diagnosed in young adulthood,
with women being preferentially affected relative to men
[2]; however, more recently the median age at which
people are diagnosed has increased to between 50 and
60 years [3]. PAH not only shortens affected individual’s
lives but also significantly impacts their quality of life,
limiting their ability to work and perform day-to-day
activities, often leading to social isolation [4].
The prevalence of PAH within Europe has been reported
as between 15 and 50 cases per million population [5].
Given that Canada does not have a PAH registry, assuming
a similar percentage of the population is affected within
Canada would result in an estimated 500 and 1800 cases.
If left untreated, the prognosis for patients with PAH is
poor. In historical registries, such as one dating from 1981,
the median survival was only 2.8 years [2]; however, based
on a more recent registry, the median survival was esti-
mated at 7 years [6]. Although survival appears to be
greater in more recent times, the factors that have con-
tributed to this difference are unclear. Significant changes
have occurred related to both the diagnosis of PAH and the
classification of the disease over this timeframe. The
management has also changed, with more awareness of the
disease, a greater number of patients treated within spe-
cialist centers, and increased therapeutic options.
Given the significant morbidity and mortality associated
with the disease, research into new therapies has been
focused on both improving patient’s quality of life, through
reducing symptoms, and increasing functioning and
extending survival.
Epoprostenol was the first PAH-specific therapy avail-
able and has been shown to improve patient outcomes,
including symptoms, hemodynamics, and survival [7].
However, epoprostenol is burdensome to administer as it
necessitates a central venous catheter (CVC) and must be
stored under refrigeration. In recent years, several oral
therapies for PAH have become available that are much
less onerous to administer, leading to epoprostenol often
being reserved for second- or third-line therapy [5]. Unlike
epoprostenol, the oral agents generally do not require
hospitalization for initiation and avoid the potentially
serious complications associated with a CVC. There are
also potential cost advantages to oral therapies as the cost
of the medication is generally lower.
Oral therapies for PAH fall into one of three categories,
namely endothelial receptor antagonists, which include
ambrisentan, bosentan and macitentan; phosphodiesterase
type-5 inhibitors, specifically sildenafil and tadalafil; and
the most recently available agent riociguat, a soluble
guanylate cyclase stimulator.
The choice of oral therapy for initiation of treatment is
challenging as there are very few head-to-head clinical trials
from which to assess the comparative effectiveness of these
agents. However, recent developments in network meta-
analysis techniques have provided a method by which the
comparative effectiveness of treatments can be estimated in
the absence of direct head-to-head trials [8]. One such recent
analysis compared the effectiveness of available PAH
treatments in patients who are naı¨ve to PAH therapies and
therefore may be helpful in guiding the choice of agent for
initiation of therapy [9]. Given the current climate of
restricted budgets for healthcare treatments, the choice of
therapeutic agent should be informed not only by the com-
parative clinical effectiveness of treatments but also the
comparative cost effectiveness, thereby ensuring maximum
efficiency of the healthcare system.
We conducted an economic analysis to address the
decision problem relating to what is the optimal therapy to
initiate treatment for PAH patients. Analysis compared the
cost effectiveness of oral PAH treatments with supportive
care alone as initial therapy for patients with New York
Heart Association functional class (FC) II and III disease in
Canada. The estimated efficacy of the oral PAH therapies
was derived from the recent network meta-analysis.
2 Methods
2.1 Analytical Framework
We developed a Markov model within Microsoft Excel
(Microsoft Corporation, Remond, WA, USA) to simulate
the long-term outcomes with treatment in the absence of
long-term clinical trial data. The model consisted of seven
states—NYHA FC I, II, III and IV with oral therapy alone,
and FC III and IV with oral therapy in combination with
epoprostenol and death (Fig. 1). With every 3-month cycle,
transition probabilities for the improvement in FC, wors-
ening in FC, and death determined the proportion of indi-
viduals who transition to different states. A 3-month cycle
length was chosen as it closely approximates the time point
at which effectiveness of PAH therapies was assessed
within the clinical trials. A proportion of patients deterio-
rating to FC IV are assumed to initiate epoprostenol ther-
apy, which was estimated at 50 % within the base-case
analysis, based on expert clinical opinion (JS/LM). With
initiation of epoprostenol, patients may improve to FC III.
Death is an absorbing state. We estimated the impact of
initial treatments for PAH through their effects on quality-
adjusted life-years (QALYs) and costs over a lifetime, and
used these values to calculate incremental cost-effective-
ness ratios (ICERs) for a comparative cost-effectiveness
analysis. Analysis was conducted from the perspective of
the Ontario healthcare system [10]. The time horizon for
the base analysis was lifetime (30 years or death), with
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future costs and outcomes discounted at a rate of 5 % per
annum [10].
The clinical experts were selected based on their
expertise in the treatment of pulmonary hypertension in
Canada, and consensus was reached through negotia-
tion with alternative values tested within sensitivity
analyses.
2.2 Patient Population
Analysis was conducted for two separate patient cohorts—
those initiating therapy in PAH FC II, and those initiating
therapy in PAH FC III. For both cohorts, it was assumed
that treatment is initiated at 50 years of age and 70 % of
the cohort is female, based on a PAH incidence registry
[11].
2.3 Comparators
Comparators were riociguat, bosentan, ambrisentan 5 and
10 mg, sildenafil and tadalafil in combination with sup-
portive care compared with supportive care alone. Maci-
tentan was not included as there were no clinical data
available specific to patients who are naı¨ve to PAH
therapy.
2.4 Model Variables
Data were required relating to disease progression, mor-
tality by FC, the relative impact of treatment on disease
progression, and adverse event rates associated with
treatment, in addition to utility values and costs for the
relevant health states within the model (Table 1).
2.4.1 Baseline Disease Progression
Patients receiving only supportive care could either
improve, by moving to a milder FC, remain within the
same FC, or their disease could worsen, represented by a
move to the next more severe FC. These rates were derived
from the placebo arms of the included clinical trials, as
estimated within the network meta-analysis.
2.4.2 Mortality
We derived age- and sex-specific annual mortality rates
from Canadian life tables [12]. To account for the
impact of the disease on mortality, we estimated the
relative rate of death with progression to FC II, III, and
IV from a recent PAH registry [13]. The registry, which
evaluated 578 PAH patients between 1982 and 2006,
found an increased rate of death compared with FC I
disease, with a hazard ratio of 4.51 (95 % CI
1.37–14.84) in FC II, 7.94 (95 % CI 2.53–24.97) in FC
III, and 11.6 (95 % CI 3.68–36.63) in FC IV. We
applied the increased risk of death with PAH to the
underlying age- and sex-specific mortality rates, and
calibrated the model to reflect the PAH registry overall
survival [14]. We also validated the survival predictions
PAH FC I 
oral therapy+SC or SC Dead 
enter from any state
PAH FC II 
oral therapy+SC or SC
PAH FC III 
oral therapy+SC or SC
PAH FC IV 
oral therapy+SC or SC
PAH FC III 
oral therapy+SC+epo
or SC+epo
PAH FC IV 
oral therapy+SC+epo
or SC+epo
Fig. 1 Model schematic. FC
New York Heart Association
functional class, PAH
pulmonary arterial
hypertension, SC supportive
care, epo epoprostenol
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Table 1 Transition probabilities, mortality rates, relative effects, costs and utilities by functional class and treatment
Costs
Resource Value Reference
Monthly cost of PAH medications
Ambrisentan 5 mg or 10 mg once daily $4028 [26]
Bosentan 62.5–125 mg bid $4219
Sildenafil 20 mg tid $1099
Tadalafil 40 mg once daily $881
Riociguat 1–2.5 mg tid $4216
Epoprostenol (initiation: 2–27 ng/kg/min; subsequent: 27–50 ng/kg/min) First 3 months: $1,758; subsequent months: $3,749
Average monitoring costs, per month (SE)
Ambrisentana $16 (4.1) [30]
Bosentanb $26 (6.6)
Epoprostenol specific costs (SE)
Initiation costsc $9759 (2439.7) [28, 29]
Infusion supply costs per day $53 (13.25) [25]
Cost to treat an episode of sepsis $20,966 (5241) [31]
Cost for replacement of CVC (every 2 years and due to infection) $166 (41.5) [29]
Average cost of supportive care medications, per monthd (SE)
Functional class II $30 (7.5) [44, 45]
Functional class III $116 (28.9)
Functional class IV $287 (71.7)
Functional class IV supportive care arm $400 (99.9)
Cost of continuing PAH care, per monthe (SE)
Functional class II $228 (57.0) [20, 29, 46]
Functional class III $727 (181.9)
Functional class IV $2267 (566.7)
Transition probabilities
Supportive care
Probability of FC improvement 0.10 [9]
Probability of FC worsening 0.12
Relative risk of FC improvement versus supportive care (95 % CrI)
Ambrisentan 5 mg 1.06 (0.61, 1.79) [9]f
Ambrisentan 10 mg 1.21 (0.62, 2.23)
Bosentan 2.05 (1.25, 3.32)
Sildenafil 3.71 (1.76, 7.29)
Tadalafil 2.67 (1.11, 5.76)
Riociguat 0.98 (0.45, 2.08)
Epoprostenol 9.42 (5.65, 17.48)
Relative risk of functional class worsening versus supportive care (95 % CrI)
Ambrisentan 5 mg 0.11 (0.03, 0.34) [9]g
Ambrisentan 10 mg 0.25 (0.05, 0.81)
Bosentan 0.46 (0.18, 1.04)
Sildenafil 0.27 (0.04, 1.10)
Tadalafil 0.45 (0.11, 1.44)
Riociguat 0.22 (0.07, 0.63)
Epoprostenol 0.40 (0.15, 0.93)
Mortality rates
Relative risk of mortality versus FC I
Functional class II vs. FC I 4.51 (1.37, 14.84) [13]
Functional class III vs. FC I 7.94 (2.53, 24.97)
Functional class IV vs. FC I 11.60 (3.68, 36.63)
Increased risk of mortality with sepsis (per person month) 0.000678 [7]
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of the model against a second PAH registry [15] (see
electronic supplementary Appendix).
2.4.3 Efficacy of Treatment
We derived the transition probabilities for each of the
medications under study by applying the relative effects of
therapy from a recent network meta-analysis, which esti-
mated the comparative impact of PAH therapies on the
improvement and worsening in FC, to the baseline proba-
bilities for FC improvement and worsening with supportive
care alone [9]. Those who did not improve or worsen
remained within their current FC for the cycle.
In the absence of long-term clinical data, assumptions
were required regarding the persistence of the impact of the
medications. Clinical trials generally measured changes in
FC at 12–16 weeks; therefore, the PAH medications were
assumed to result in improvements in FC during the first
cycle of the model. Clinical trial evidence also supports
that these medications reduce the risk of FC worsening
[16–19]. Although the duration of this effect has not been
well-documented within long-term controlled trials, within
the base-case analysis, we assumed that it persisted
throughout the lifetime of the patient. These assumptions
were based on expert clinical opinion (JS/LM), are in line
with other cost-effectiveness analyses, and were tested
within sensitivity analyses [20].
Studies have found conflicting results with respect to
the effect of treatment on survival. A meta-analysis from
2009 reported a 43 % reduction in mortality with PAH-
targeted treatments, whereas a systematic review of the
literature from 2007 found little evidence for a survival
benefit with PAH-targeted treatments [21, 22]. With this
model, we assumed that treatments had no independent
effect on mortality but rather affected mortality through
delaying the progression of the disease. This avoided
double counting any impact of the medications on
survival.
2.4.4 Adverse Events
Adverse events that have a clear impact on utility and
costs, specifically those that were considered serious, were
included within the analysis. Adverse events for oral PAH
therapies were not included as they were generally minor
and were comparable to those with placebo or supportive
care. In patients receiving epoprostenol there is an
increased risk of infections associated with the presence of
a CVC and the potential for the severe complication of
sepsis, which is associated with increased costs, a utility
decrement, and increased mortality. Within the model, we
included the costs for CVC infections, as well as the costs,
disutility, and increased mortality associated with sepsis, in
patients receiving epoprostenol.
2.4.5 Utility Values
Although many clinical trials of PAH therapies report
having measured quality of life, none have reported the
impact of treatment in a format that would allow estimation
Table 1 continued
Costs
Resource Value Reference
Utilities
Functional class I 0.73 (0.64, 0.82) [23]
Functional class II 0.67 (0.57, 0.77)
Functional class III 0.60 (0.50, 0.70)
Functional class IV 0.52 (0.43, 0.61)
Disutility with sepsis, over 3 months 0.108 [24]
CrI credible interval, PAH pulmonary arterial hypertension, bid twice daily, tid three times daily, CVC central venous catheter, SE standard error, NYHA
New York Heart Association, FC functional class
All costs are expressed in Canadian dollars
a Monthly liver function tests and annual pregnancy test with ambrisentan
b Monthly liver function tests and monthly pregnancy tests with bosentan
c Assumed in 50 % of patients, epoprostenol is initiated within the hospital, and for 50 % through day surgery. Also includes training and CVC insertion
costs
d Warfarin 5 mg daily in 53 % of patients, furosemide 100 mg daily in 69 % of patients, digoxin 0.125 mg daily in 26 % of patients, and home oxygen
therapy in 5 % of patients with NYHA FC II, 27 % of patients with NYHA FC III and 71 % of patients with NYHA FC IV receiving PAH-specific
therapies, and 100 % of patients with NYHA FC IV receiving supportive care
e Includes general practitioner visits, specialist visits, nurse visits, hospitalizations, emergency room visits, and therapeutic procedures (echocardiograph
and blood work)
f Fixed effect model, naı¨ve population network meta-analysis, Table 184, Appendix 11
g Fixed effect model, naı¨ve population network meta-analysis, Table 188, Appendix 11
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of QALYs. We therefore assigned utility values based on
the severity of PAH, as measured by FC. These were
obtained from a published study deriving utility values
using the SF-36 with 177 Australian PAH patients [23].
Within this study, the utility value was shown to decrease
with increasing severity of PAH, as measured by a wors-
ening FC.
In addition, for those developing sepsis while on epo-
prostenol, a utility decrement of 0.108 was applied for the
3-month cycle in which the event occurred. This corre-
sponds to an annual utility decrement of 0.027 [24].
2.4.6 Cost Variables
The costs associated with initiation of therapy, ongoing
treatment, and monitoring the disease were also included.
The costs related to the diagnosis of PAH were not inclu-
ded within the model as we assumed they would be
incurred by all PAH patients, regardless of the initial
treatment strategy, and therefore would not impact the
relative cost effectiveness.
According to expert clinical opinion (JS/LM), oral
therapies are generally initiated in the patient’s home and
therefore do not incur any costs for initiation; however, a
portion of patients are typically hospitalised during initia-
tion of epoprostenol. We therefore included the hospital-
ization and healthcare professional costs for initiation of
epoprostenol.
For the cost of PAH therapies, we included both the
medication costs, with mark-up and dispensing fees, and
the cost of administration supplies for epoprostenol. Med-
ication and diluent costs were obtained from a provincial
drug formulary, and the cost of equipment was derived
from a previous Canadian analysis [25, 26].
With both the supportive care strategy and each of the
PAH treatment strategies, the costs of non-PAH-specific
therapies, including warfarin in 53 % of patients, digoxin
in 26 % of patients and furosemide in 69 % of patients,
were also incorporated [27]. Oxygen use was assumed to
vary based on FC, with 5 % of patients receiving it in FC
II, 27 % in FC III, and 71 % in FC IV for those receiving
PAH treatment strategies, and 100 % in FC IV in those in
the supportive care strategy [20].
The costs of supportive care for patients diagnosed with
PAH vary by FC. A recent UK study reported resource use
by patients with FC II, III, and IV PAH under the cate-
gories of hospitalizations, specialist and non-specialist
clinic visits, nurse visits, and emergency room visits [20].
We applied current Canadian costs to this resource data to
estimate the average ongoing cost by FC [28, 29]. Within
the base-case analysis, in the absence of conflicting data,
we assumed that there were no ongoing costs for patients
within FC I. This assumption was tested in sensitivity
analyses. Patients were also assumed to undergo a standard
set of PAH monitoring tests (renal function tests, blood
tests, echocardiogram) for which current Canadian costs
were applied [29, 30]. For each patient developing sepsis, a
treatment cost of Can$19,457 was incorporated [31]. For
CVC infections, it was assumed that the catheter would be
replaced both when the infection occurred and every
2 years in the absence of an infection, at a cost of Can$166
[29].
Costs were reported in 2013 Canadian dollars with any
inflation adjustments based on the Bank of Canada Infla-
tion Calculator [32].
2.5 Sensitivity Analysis
Deterministic sensitivity analyses were conducted to assess
the impact of parameter uncertainty and structural uncer-
tainty on the cost-effectiveness outcome. Alternative
assumptions regarding the persistence of the impact of
treatment on FC worsening, an alternative source of utility
values [33], a generic price for bosentan and epoprostenol,
and varying the epoprostenol dose to the extremes of the
prescribed dosage range were tested. Structural uncertainty
was examined through producing undiscounted estimates
of cost and QALYs, reducing the time horizon to 10 years,
and by assuming either no patients or all patients initiated
epoprostenol therapy upon deterioration to FC IV.
A probabilistic sensitivity analysis with 5000 replica-
tions was conducted in which each model input parameter
was represented by a probability distribution [34]. Standard
distributions were used for each input parameter: log nor-
mal distribution for odds ratios and relative risks, gamma
distributions for costs, and beta distributions for utilities.
As the source documents for the costs did not contain
estimates of uncertainty, we estimated a standard error at
25 % of the mean [34].
3 Results
The results of the cost-effectiveness analysis were similar
for patients initiating therapy with both FC II PAH and FC
III (Table 2). In both cases, sildenafil was the least costly
strategy and produced the greatest QALYs, thereby domi-
nating all other therapies (Fig. 2). The increase in QALYs
is primarily due to the impact of sildenafil in delaying
disease progression as it produced a greater effect on FC
improvement than all other treatments. The lower costs can
be attributed primarily to the lower acquisition cost of
sildenafil, which is approximately one-third of that of other
PAH therapies (Table 3).
Extensive sensitivity analyses found the results to be
robust to changes in most model assumptions. Sildenafil
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remained the dominant treatment in all sensitivity analyses,
except when alternative assumptions regarding the per-
centage of patients initiating epoprostenol and the waning
of the treatment effect were incorporated. If epoprostenol is
not introduced upon deterioration to FC IV in any treat-
ment strategy, the ICER increases to Can$29,035 per
QALY for sildenafil versus supportive care in FC II, and to
Can$45,349 per QALY in FC III.
When the treatment effect was assumed to wane at
various rates after the first 18 months of therapy, reaching
that of supportive care after either a further 10 years or a
further 5 years in some cases, sildenafil no longer domi-
nated supportive care. However, sildenafil remained the
most cost-effective treatment option, with an ICER of less
than Can$35,000 per QALY versus supportive care in both
waning scenarios, in patients with FC II and III disease.
Full details of the sensitivity analysis are provided in the
electronic supplementary Appendix.
In the probabilistic sensitivity analysis, sildenafil was
the most cost-effective therapy in the majority of
Table 2 Results by PAH functional class at initiation of therapy
Treatment Discounted costs ($) Discounted QALYs Incremental cost per
QALY compared with sildenafil
Functional class II
Sildenafil $146,254 4.663
Tadalafil $153,245 4.002 Dominated by sildenafil
Supportive care $155,156 3.218 Dominated by sildenafil
Ambrisentan 5 mg $377,187 4.634 Dominated by sildenafil
Ambrisentan 10 mg $377,523 4.217 Dominated by sildenafil
Riociguat $388,491 4.244 Dominated by sildenafil
Bosentan $406,282 3.904 Dominated by sildenafil
Functional class III
Sildenafil $181,119 3.284
Tadalafil $200,584 3.013 Dominated by sildenafil
Supportive care $204,285 2.687 Dominated by sildenafil
Ambrisentan 5 mg $351,573 3.180 Dominated by sildenafil
Ambrisentan 10 mg $376,884 3.043 Dominated by sildenafil
Riociguat $383,582 3.045 Dominated by sildenafil
Bosentan $412,979 2.960 Dominated by sildenafil
All costs are expressed in Canadian dollars
Dominated more costly and fewer QALYs, QALY quality-adjusted life-year, PAH pulmonary arterial hypertension
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replications at willingness-to-pay values from Can$0 to
Can$200,000 per QALY in both FC II and FC III PAH
(Fig. 3). Tadalafil was the only other therapy, apart from
supportive care, that had a greater than 0 % chance of
being cost effective; however, the probability for tadalafil
ranged between only 20 % and 30 % of replications.
4 Discussion
We found sildenafil to be the most cost-effective treatment
for first-line therapy in both patients with FC II and those
with FC III PAH. The probabilistic sensitivity analysis
identified considerable uncertainty surrounding the esti-
mates of the incremental costs and QALYs associated with
therapies, although there was little uncertainty relating to
finding that sildenafil was the most cost-effective treat-
ment, followed by tadalafil.
The uncertainty in the estimates was primarily due to
uncertainty in the estimated effectiveness of treatments as
opposed to the estimated costs. There were wide confi-
dence intervals surrounding the estimates of improvement
and worsening FC derived from the network meta-analysis.
This stemmed not only from the limited number of well-
designed clinical trials that were available for inclusion
within the analysis but also due to the substantial hetero-
geneity in design and patient population within the trials.
To address these issues, analysis focused on the patients
who were naı¨ve to PAH therapies and was conducted
stratified by FC. The results were shown to be relatively
insensitive to stratification by FC. Results were sensitive to
assumptions regarding the proportion of patients initiating
epoprostenol upon deteriorating to FC IV, and assumptions
regarding the persistence of the PAH therapy effectiveness
over the long-term. Even given this uncertainty, sildenafil
was the most cost-effective therapy compared with other
oral PAH therapies in all scenarios.
These results are not dissimilar to those of previously
published models that focused on other jurisdictions;
however, previous studies have been limited with respect to
the PAH therapies under consideration, and examined only
patients with FC III or IV disease.
In a previous cost-utility analysis of PAH treatments,
Garin and colleagues found that sildenafil was the most
cost-effective therapy from a US healthcare system per-
spective in patients with PAH FC III and IV [35]; this
analysis did not include either riociguat or tadalafil within
the possible treatment strategies. In their analysis, the
transition probabilities for all drugs were based on adjust-
ing the rate of improvement and worsening in FC with
bosentan by the relative risk of improvement in the 6-min
walk test compared with bosentan. Our study used a more
robust approach of sourcing data from studies that had
directly measured the rate of improvement and worsening
Table 3 Breakdown of discounted lifetime costs by treatment at initiation
Functional
class
Item Ambrisentan
5 mg
Ambrisentan
10 mg
Bosentan Sildenafil Tadalafil Riociguat Supportive
care
II PAH-specific drugs $341,088 $317,768 $314,817 $93,602 $66,920 $334,140 $0
Monitoring/therapeutic proceduresa $3131 $2913 $3484 $1768 $1573 $1643 $1394
Hospital/ER/clinic visitsb $23,882 $32,953 $42,901 $29,213 $41,522 $31,638 $63,053
Supportive care drugsc $3608 $4886 $6182 $4332 $5991 $4711 $10,833
Epoprostenold $5478 $19,002 $38,899 $17,339 $37,239 $16,358 $79,921
III PAH-specific drugs $261,295 $253,884 $261,209 $72,780 $55,154 $265,827 $0
Monitoring/therapeutic proceduresa $2385 $2316 $2878 $1367 $1291 $1300 $1200
Hospital/ER/clinic visitsb $51,793 $59,704 $66,052 $53,580 $64,352 $58,926 $79,770
Supportive care drugsc $8052 $8883 $9500 $7971 $9720 $8825 $13,986
Epoprostenold $28,049 $52,098 $73,341 $45,421 $70,518 $48,703 $109,328
ER emergency room, PAH pulmonary arterial hypertension, NYHA New York Heart Association FC functional class
All costs are expressed in Canadian dollars
a Includes monthly liver function tests for bosentan and ambrisentan, monthly pregnancy test for bosentan, and annual pregnancy tests for
ambrisentan; echocardiograms, renal function, and blood work for all therapies
b Includes general practitioner visits, specialist visits, nurse visits, hospitalizations, emergency room visits, therapeutic procedures (echocar-
diograph and blood work)
c Warfarin 5 mg daily in 53 % of patients, furosemide 100 mg daily in 69 % of patients, digoxin 0.125 mg daily in 26 % of patients, and home
oxygen therapy in 5 % of patients with NYHA FC II, 27 % of patients with NYHA FC III and 71 % of patients with NYHA FC IV receiving
PAH-specific therapies, and 100 % of patients with NYHA FC IV receiving supportive care
d Epoprostenol was initiated in 50 % of patients upon deterioration to FC IV in those receiving PAH-specific therapies and in 100 % of patients
receiving only supportive care
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FC with each of the PAH therapies in patients naı¨ve to
PAH-specific treatment. Network meta-analysis provided a
statistical approach to consolidate the information available
from both head-to-head and placebo-controlled trials,
allowing estimation of the comparative effects of treat-
ments that had yet to be studied head-to-head [36].
In 2009, a UK study compared the cost effectiveness of
PAH treatments, specifically epoprostenol, iloprost, sitax-
entan, bosentan and sildenafil, individually versus sup-
portive care in patients with FC III PAH [20]. Sildenafil
dominated supportive care within this analysis, being both
less costly and producing greater QALYs. When bosentan
was compared with supportive care, the resulting ICER
was £27,000 per QALY (2006 costs). This study differed
from the current analysis in that it was not designed to
allow a direct comparison of the cost effectiveness of PAH
treatments relative to each other, but only relative to sup-
portive care. Additionally, unlike the current study, which
incorporated a survival benefit with treatment based on the
treatment impact on FC worsening, the UK study derived a
survival benefit from open-label follow-up studies [37].
There may be inherent bias in estimating long-term sur-
vival from this type of data as patients who enter into long-
term study arms often differ significantly from the popu-
lation included within randomised clinical trials [38, 39].
Given the lack of solid follow-up data, we felt the most
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Fig. 3 Cost-effectiveness
acceptability curve by a PAH
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appropriate way of incorporating a potential survival ben-
efit was via directly measured effects on FC improvement
and worsening.
The current analysis provides cost-effectiveness esti-
mates stratified by initial FC for both class II and III. This
stratified analysis is of particular interest given recent
changes in reimbursement in some jurisdictions which
provide differential coverage based on FC. The Ontario
Drug Benefit program does not reimburse any PAH med-
ication for patients with FC II disease but provides cov-
erage for some PAH-specific medications for those with FC
III disease, under its exceptional access program [40]. The
results of the current analysis provide evidence against
differential reimbursement between FC II and III.
We chose to use FC as the primary outcome for the
estimation of gains in QALYs, with treatment based on the
fact that FC has been established as a clinically relevant
outcome in the treatment of PAH [5]. Although the 6-min
walk test has often been the primary efficacy variable
within PAH clinical trials, its relevance has been ques-
tioned in recent years due to its unclear relationship with
clinically relevant outcomes such as hospitalizations,
mortality, transplantation, or need for rescue therapy [41].
On the other hand, functional class has the benefit of not
only having been shown to be associated with mortality but
also with quality-of-life measures in PAH [23].
Aswith allmodelling studies, the results are limited by the
availability of data for populating the model. The reporting
of results within clinical trials necessitated the assumption
that the impact of treatment on improvement or worsening in
FC overall could be applied regardless of the initial FC of the
patient’s disease. In the absence ofmore detailed reporting of
results, and given that the majority of patients within the
clinical trials were in FC II or III upon initiation of therapy,
we consider this a valid and necessary assumption.
A second limitation of the analysis is that it included
only PAH medication dosages that are therapeutically
approved within Canada. In some cases, particularly with
respect to sildenafil, there is evidence that doses used
within clinical practice may be higher than the approved
dose. However, the effectiveness data for the network
meta-analysis was derived from studies with the approved
doses and therefore this dose was used within the analysis.
Third, the model incorporated only the impact of
adverse events associated with epoprostenol. This decision
was based on evidence from meta-analyses which found
that the rates of serious adverse events and discontinuations
due to adverse events were comparable between oral PAH
treatments and placebo or supportive care [42, 43]. Con-
sequently, the omission of these adverse events should not
affect the estimate of QALYs or costs, or bias the results.
The evidence for both the network meta-analysis and
this economic evaluation could be strengthened through the
conduct of well-designed head-to-head randomised con-
trolled trials. Both were limited by the few studies avail-
able and the limited duration of the studies. Furthermore,
the direct measurement of the impact of treatments on the
quality of life in patients using a validated instrument,
which may be used to estimate the QALY gain with
treatment, would provide greater insight into the effec-
tiveness of these therapies.
5 Conclusion
The results indicate that initiation of therapy with sildenafil
in patients with FC II and III PAH would result in probable
cost savings compared with other oral PAH therapies. This
is an important finding as the costs associated with thera-
pies for PAH are considerable. These findings also do not
support differential funding of PAH therapies for patients
with FC II versus FC III disease. It would seem appropri-
ate, based not only on clinical trial evidence but also with
respect to cost effectiveness, to initiate therapy with
sildenafil, provided it is not contraindicated.
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